High Throughput Screening (HTS) – Where next? By Dr Mark Beggs After approximately a decade of maturation and a three orders of magnitude increase in capabilities, High Throughput Screening (HTS) is now an established discipline within pharmaceutical discovery. But opposing stresses exist within the screening world; the resolution… Read More
The Integration Abyss By Dr Scott D. Kahn The long-standing disconnect between target discovery/characterisation and compound discovery is a major challenge facing the pharmaceutical industry in its quest to develop innovative therapies from the wealth of information flowing from the human genome. There is enormous… Read More
Discovery Research in the Co-Genomic Era – Biology goes industrial By Dr Timothy Wells and Dr Georg Feger The parallel between the search for gold in the last century and drug discovery in the co-genome era is very clear. As with all gold rushes the rewards will… Read More
By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let… Read More
The role of toxicogenomics in drug discovery By Dr Robin E. Neft and Dr Spencer Farr The information that toxicogenomics can bring in terms of toxic mechanisms, safety and efficacy must ultimately have a major impact on the drug discovery process. Large scale genome sequencing has… Read More
By Dr Ashok R. Dongre and Dr Stanley A. Hefta The genomic sequencing efforts spawned the field of proteomics by providing the basic blueprint for protein sequences, enabling proteomics to become the contemporary technology for studying the underlying mechanisms of disease. This review… Read More
Harnessing the CRO Intellect By Ian Lennox and Dr Nigel Brown There is no question that pharmaceutical companies are qualified to perform their own discovery and preclinical research. However, to fully exploit the new technologies in the early research phases, to maximise drug leads, and to minimise… Read More
HTS a strategy for drug discovery By Dr AR Knight, Cerebrus Ltd Whichever technologies are implemented, high throughput screening is set to become one of the cornerstones of drug discovery, however deciding which strategy to implement will provide many headaches. This article concentrates on screens identifying the… Read More
By Jennie Gwynn and Peter J Hylands Putting aside the excitement surrounding the human genome, in the near future we may well start to see the emergence of a new class of prescription medicine containing complex mixtures of plant extracts. This article discusses the important role that… Read More
By Matthias Mann, Protein Interaction Laboratory (PIL), University of Southern Denmark Affinity proteomic methods can translate genomic data into validated targets for drug discovery. Baits such as tagged gene product or small molecules obtained from cell-based assays are used to purify interacting proteins. Read More
Using Expression Databases for Drug Discovery By Dr Greg Lennon Reference databases are being built cataloguing the amount of RNA each gene makes under different conditions and in different individuals. These databases can be mined easily and effectively to aid the drug discovery process. Read More